Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHCC for Clearance of High Risk-HPV Infections in Chinese Females
NCT04633330Recruiting
- Sponsor
- Shandong University
- Start
- Oct 2020
- Primary completion
- Jun 2024
- Modality
- Botanical Extract, Nutraceutical
- Countries
- 1
01
Overview
Randomised, double-blind trial of active hexose correlated compound in human papillomavirus infection (2 arms), sponsored by Shandong University. Primary endpoint: High risk human papillomavirus (HR-HPV) infection testing at 6 months. Started Oct 2020; status: recruiting.
02
Drugs
active hexose correlated compound
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04633330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633330.